The Editor's roundtable: Advances in stem cell therapy for treatment of cardiovascular disease

Vincent E. Friedewald; Joshua M. Hare; Leslie W. Miller; Howard T. Walpole; James T. Willerson; William C. Roberts

doi:10.1016/j.amjcard.2012.06.046

The Editor's roundtable: Advances in stem cell therapy for treatment of cardiovascular disease

Vincent E. Friedewald, Joshua M. Hare, Leslie W. Miller, Howard T. Walpole, James T. Willerson, William C. Roberts

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	807-816
Number of pages	10
Journal	American Journal of Cardiology
Volume	110
Issue number	6
DOIs	https://doi.org/10.1016/j.amjcard.2012.06.046
State	Published - Sep 15 2012
Externally published	Yes

Bibliographical note

Funding Information:
Dr. Hare: There is a very rapid proliferation of enthusiasm for this therapy among both the medical community and among patients. The medical community has a major responsibility to aggressively perform the appropriate studies that could lead to clinical approval of this therapy. Some forms of SC therapy have been approved in Europe. I predict that we will have approval in the United States for SC treatments sooner than most experts believe, perhaps within the next 3 to 5 years. One of the most important initiatives is the Cardiovascular Cell Therapy Research Network (CCTRN), funded by the National Institutes of Health. The CCTRN has devoted substantial resources to a multicenter network that Dr. Willerson, Dr. Miller, and I are honored to participate in. In this consortium, SC research trials can be conducted very quickly.

Funding Information:
This article is supported by a grant from the Okyanos Heart Institute, Freeport, The Bahamas.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.amjcard.2012.06.046

Find It

Find It at U of M Libraries

Cite this

@article{5e9b73aa00ee4a8eb7627f5f1631ac79,

title = "The Editor's roundtable: Advances in stem cell therapy for treatment of cardiovascular disease",

author = "Friedewald, {Vincent E.} and Hare, {Joshua M.} and Miller, {Leslie W.} and Walpole, {Howard T.} and Willerson, {James T.} and Roberts, {William C.}",

note = "Funding Information: Dr. Hare: There is a very rapid proliferation of enthusiasm for this therapy among both the medical community and among patients. The medical community has a major responsibility to aggressively perform the appropriate studies that could lead to clinical approval of this therapy. Some forms of SC therapy have been approved in Europe. I predict that we will have approval in the United States for SC treatments sooner than most experts believe, perhaps within the next 3 to 5 years. One of the most important initiatives is the Cardiovascular Cell Therapy Research Network (CCTRN), funded by the National Institutes of Health. The CCTRN has devoted substantial resources to a multicenter network that Dr. Willerson, Dr. Miller, and I are honored to participate in. In this consortium, SC research trials can be conducted very quickly. Funding Information: This article is supported by a grant from the Okyanos Heart Institute, Freeport, The Bahamas. ",

year = "2012",

month = sep,

day = "15",

doi = "10.1016/j.amjcard.2012.06.046",

language = "English (US)",

volume = "110",

pages = "807--816",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - The Editor's roundtable

T2 - Advances in stem cell therapy for treatment of cardiovascular disease

AU - Friedewald, Vincent E.

AU - Hare, Joshua M.

AU - Miller, Leslie W.

AU - Walpole, Howard T.

AU - Willerson, James T.

AU - Roberts, William C.

N1 - Funding Information: Dr. Hare: There is a very rapid proliferation of enthusiasm for this therapy among both the medical community and among patients. The medical community has a major responsibility to aggressively perform the appropriate studies that could lead to clinical approval of this therapy. Some forms of SC therapy have been approved in Europe. I predict that we will have approval in the United States for SC treatments sooner than most experts believe, perhaps within the next 3 to 5 years. One of the most important initiatives is the Cardiovascular Cell Therapy Research Network (CCTRN), funded by the National Institutes of Health. The CCTRN has devoted substantial resources to a multicenter network that Dr. Willerson, Dr. Miller, and I are honored to participate in. In this consortium, SC research trials can be conducted very quickly. Funding Information: This article is supported by a grant from the Okyanos Heart Institute, Freeport, The Bahamas.

PY - 2012/9/15

Y1 - 2012/9/15

UR - http://www.scopus.com/inward/record.url?scp=84865455865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865455865&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2012.06.046

DO - 10.1016/j.amjcard.2012.06.046

M3 - Comment/debate

C2 - 22818841

AN - SCOPUS:84865455865

SN - 0002-9149

VL - 110

SP - 807

EP - 816

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 6

ER -

The Editor's roundtable: Advances in stem cell therapy for treatment of cardiovascular disease

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this